Snowflake published a 13-point framework for evaluating agentic AI vendors in healthcare and life sciences. No prediction venue lists live odds or volume tied to this guidance. What moved is vendor advice, not a deployment or revenue result, which limits any market signal. Not financial advice. Markets move fast.
The obvious reading is that buyers now have a clean checklist for safe agents. I do not buy it.
Snowflake says agents now act directly across trials, provider operations, patient services and claims, so buyers must probe data readiness and governance. Industry Principal Patrick Kovalik positions the 13 points for CEOs, CTOs and CDOs moving from narrow pilots to complex workflows. The core promise, tied to Cortex AI, is process data where it lives, keep one semantic layer, and swap models without re-platforming.
What is missing is proof.
Snowflake offers process advice without a named deployment, cycle-time gain or cost figure. That gap matters.
For the clean-checklist story to hold, in-place processing would need to cover notes, images, audio and logs with permissions intact across models. Fair point: model flexibility and shared metrics are real buyer pain, and Snowflake names them clearly.
Only about 130 vendors among thousands promoting agentic tech offered genuinely agentic capabilities at the time of a Gartner assessment cited by DistilInfo. That scarcity is why a vendor-authored buying guide deserves extra scrutiny.
If you are buying, pilot one workflow with your own access logs and success metric before you trust any 13-point promise.





